NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a "neutral" rating on the stock.
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
Novocure Reports First Quarter 2024 Financial Results